Wipe-sampling procedure optimisation for the determination of 23 antineoplastic drugs used in the hospital pharmacy.
cytotoxics
surface contamination
wipe sampling
Journal
European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
10
05
2019
revised:
02
07
2019
accepted:
09
07
2019
entrez:
20
2
2021
pubmed:
21
2
2021
medline:
2
4
2022
Statut:
ppublish
Résumé
Optimise a wipe sampling procedure to evaluate the surface contamination for 23 antineoplastic drugs used in the hospital pharmacy. The influence of various parameters (ie, sampling device, sampling solution, desorption modes) was evaluated using a validated liquid chromatography-mass spectrometry (LC-MS/MS) method able to quantify 23 antineoplastic drugs widely used in the hospital pharmacy: 5-fluorouracil, busulfan, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, etoposide phosphate, fludarabine phosphate, ganciclovir, gemcitabine, idarubicin, ifosfamide, irinotecan, methotrexate, paclitaxel, pemetrexed, raltitrexed, topotecan and vincristine. Best conditions were tested with real samples from a hospital pharmacy chemotherapy compounding unit. Polyester swabs (TX714 and TX716) gave satisfactory results for the desorption step for all compounds with mean recoveries of 90% and 95%, respectively. For the wiping step, higher recoveries were obtained using TX716 and isopropanol 75% as wiping solution. As anticipated, most intense contaminations were found close to the chemotherapy production site, on surfaces the most frequently in contact with operators' hands. Wipe sampling method was successfully developed and applied to real samples to determine surface contamination with 23 antineoplastic agents in trace amounts.
Identifiants
pubmed: 33608437
pii: ejhpharm-2019-001983
doi: 10.1136/ejhpharm-2019-001983
pmc: PMC7907690
doi:
Substances chimiques
Antineoplastic Agents
0
Ifosfamide
UM20QQM95Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
94-99Informations de copyright
© European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Arh Hig Rada Toksikol. 2018 Sep 1;69(3):226-237
pubmed: 30285941
CA Cancer J Clin. 2006 Nov-Dec;56(6):354-65
pubmed: 17135692
Am J Health Syst Pharm. 2012 Oct 1;69(19):1665-70
pubmed: 22997120
J Pharm Biomed Anal. 2019 Feb 5;164:395-401
pubmed: 30439666
Ann Work Expo Health. 2017 Oct 1;61(8):1003-1014
pubmed: 29028255
J Occup Environ Hyg. 2017 Mar;14(3):159-174
pubmed: 27676216
Environ Monit Assess. 2017 Jan;189(2):52
pubmed: 28063118
Anal Bioanal Chem. 2012 Mar;402(8):2499-509
pubmed: 21701850
Workplace Health Saf. 2018 May;66(5):264
pubmed: 29562844
Am J Health Syst Pharm. 2018 Dec 15;75(24):1996-2031
pubmed: 30327293
J Pharm Biomed Anal. 2019 Aug 5;172:139-148
pubmed: 31035095